Kornimate/medical-research-clean huggingface dataset:
acupuncture for dizziness and vertigo in emergency department

Conditions: Dizziness and Vertigo

Summary: this study was conducted at china medical university hospital, taiwan, between january 2019 and december 2023, with 345 patients diagnosed with dizziness and vertigo (icd-10 codes r42 and h81). patients received acupuncture in addition to standard western medical care. the visual analogue scale (vas) was used to assess symptom severity before and after the acupuncture intervention. secondary analyses explored the influence of icd-10 classification, gender, and seasonality on treatment outcomes.


Eligibility criteria:
inclusion criteria: patients who were diagnosed as icd number r42 and h81 exclusion criteria: patients who were not suitable to accept acupuncture or refused to accept acupuncture
dose response study in japanese patients

Conditions: Type 2 Diabetes

Summary: this is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients with type 2 diabetes. improvement in dyslipidemia will be evaluated. the study comprises a 2-week screening period, 4-week placebo run-in, a 12-week randomized, double blind, parallel group, multi-center, placebo-controlled treatment period, and a 3-week follow-up.


Eligibility criteria:
inclusion criteria: * provision of a written informed consent * men or women who are \>=18 years of age * female patients: postmenopausal, hysterectomized * diagnosed with type 2 diabetes * treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral anti-diabetic agents exclusion criteria: * type 1 diabetes * new york heart association heart failure class iii or iv * treatment with chronic insulin * history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin) * history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells) * creatinine levels above twice the normal range * creatine kinase above 3 times the upper limit of normal * received any investigational product in other clinical studies within 12 weeks * any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
the magnitude of effect of pcp counseling on participation rate and sedation rate in colonoscopy-based screening program

Conditions: Colorectal Neoplasms

Summary: the purpose of this study is to assess the impact of physician's counseling on participation and utilization of sedation in a primary colonoscopy-based colorectal cancer (crc) screening program

participation rate is one of the major factors influencing the effectiveness of screening programs. participation rates in crc screening, including primary colonoscopy programs, remain suboptimal. it is known that one of the strongest predictors of crc screening participation rate is a physician, especially primary care physician (pcp), recommendation. engaging a pcp tends to improve participation rate in organized and opportunistic cancer screening programs. to our best knowledge there are no randomized controlled trials, dedicated specifically to assess the effect of physician's counseling on participation rate in primary colonoscopy crc screening programs. there is also no data on the impact of physician's counseling on patient's decision to choose unsedated (not in sedation) or sedated colonoscopy. in this study we aimed to quantitatively estimate the impact of a pcp's counseling on screening participation rate and utilization of sedation in the opportunistic primary crc screening program when compared to the effect obtained by using a standardized information leaflet only.

Eligibility criteria:
inclusion criteria: * 50-65 years of age exclusion criteria: * colonoscopy within last 10 years * change in bowel habits in the previous six months * a visible blood in stool (unless related to known hemorrhoids) * anemia or weight loss of unknown cause * severe comorbid conditions making subject ineligible for screening colonoscopy

Keywords: colorectal neoplasms colonoscopy early detection of cancer patient selection patient participation physicians, primary care conscious sedation
identification of gut microbiome biomarkers associated to acquisition of enterobacteriae highly resistant to third generation cephalosporines following ceftriaxone treatment.

Conditions: Patients Receiving Ceftriaxone in Hospital Emergency Unit

Summary: patients receiving ceftriaxone 1 gram or 2 grams per day during their presence in emergency unit of hospital whatever their medical condition, will be included. rectal swabs will be collected at inclusion and at days 5 and 30 to perform analysis. analysis will be performed to characterize gut microbiome in order to detect intestinal microbiome profiles significantly associated with protection against colonization by third generation cephalosporin resistant enterobacteriae.


Eligibility criteria:
inclusion criteria: * age 18 years * able to comply with study requirement and to provide informed consent * outside the context of tutorship and / or guardianship, affiliated to the social security regime and having consented to participate in the arcmi study. * patient receiving ceftriaxone (1 gram or 2 grams per day) in the emergency department exclusion criteria: * patients with acute anorectal pathology incompatible with the swabbing strategy or digital rectal examination. * prescription of another dosage of ceftriaxone (more than 2 grams per day) * patient with inflammatory bowel disease * allergy or contraindication to betalactamines and cephalosporins
pals for nutrition education

Conditions: Nutrition Disorders

Summary: the overall goal of this inquiry is to determine whether pals is more effective than comparable online resources at educating patients in the outpatient clinic setting about nutrition. participants will be randomly assigned to view either a pals article or webmd article on the same nutrition topic. participants will then fill out a post-survey to assess knowledge uptake and attitudes regarding healthy eating.


Eligibility criteria:
inclusion criteria: * patient ≥ 18 years of age. * ability to speak and read in english. * passing the screener - mini-mental status examination. * patient at wcima clinic on upper east side of manhattan, ny. exclusion criteria: * non-english speakers * inability to read in english * being younger than 18 * not passing the screener * not a patient at wcima clinic on upper east side of manhattan, ny.
mr guided focused ultrasound surgery in the treatment of uterine fibroids: software v4.2 validation

Conditions: Uterine Fibroids; Uterine Leiomyomas

Summary: the goal of this study is to validate the new exablate application software v4.2 by developing additional data that shows the safety of this treatment. the exablate is intended to ablate uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure. patients must have a uterine size of less than 24 weeks and not seeking treatment for reasons of improving fertility.


Eligibility criteria:
inclusion criteria: 1. women who present with symptomatic uterine fibroids and are not seeking treatment for the reason of improving fertility. 2. able and willing to give consent and able to attend all study visits. 3. patient is pre or peri-menopausal (within 12 months of last menstrual period). 4. able to communicate sensations during the exablate procedure. 5. uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone). 6. fibroids(s) clearly visible on non-contrast mri. exclusion criteria: 1. metallic implants that are incompatible with mri 2. sensitive to mri contrast agents 3. severe claustrophobia that would prevent completion of procedure in mr unit 4. who are pregnant or desire to become pregnant in the future. pregnancies following exablate treatment could be dangerous for both mother and fetus. 5. pedunculated fibroids 6. active pelvic inflammatory disease (pid) 7. active local or systemic infection 8. known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia 9. intrauterine device (iud) anywhere in the treatment path 10. dermoid cyst of the ovary anywhere in the treatment path 11. extensive abdominal scarring that cannot be avoided by redirection of the beam (e.g., due to caesarean section or repeated abdominal surgeries) 12. undiagnosed vaginal bleeding

Keywords: fibroids uterine leiomyomas exablate mrgfus
the neural basis of lumbosacral proprioceptive impairment in recurrent low back pain

Conditions: Low Back Pain

Summary: low back pain (lbp) is a well known health problem in western society that is significantly responsible for socio-economic problems like absenteeism and disability. the lifetime prevalence of lbp is 60-80% and approximately 85% of this lbp has a "non-specific" character whereby the underlying causes and risk factors cannot be demonstrated. while many people recover within a month, most individuals will have recurrence within a year with more severe symptoms. this might be due to insufficient knowledge of the underlying mechanisms. impaired proprioception, the ability to discern body/limb positions and movements, may cause and maintain lbp shown by an altered postural control strategy. specifically, patients with lbp rely more on proprioceptive signals from the ankles due to less reliable proprioceptive input of proximal segments. moreover, they show a decreased variability in postural control and less postural robustness, while variability is a prerequisite for optimal functioning of biological systems. however, further clarification of the neural correlates is necessary. deficits in proprioception, as found in a subgroup of patient with lbp, are associated with a decreased ability of the brain to process proprioceptive inputs. the aim of this project is to clarify the central changes in individuals with recurrent non-specific low back pain and healthy controls. to evaluate these central changes mri techniques (3dtfe, dti and rs-fmri) will be used. in addition, the association between central changes and postural control tasks will be evaluated.


Eligibility criteria:
inclusion criteria persons with low back pain: * age: 20-50 year * at least 6 months of low back pain with/without referred pain in buttock/thigh * at least 3 episodes of disabling low back pain * at least a score of 14% on the oswestry disability index * willingness to sign the informed consent * met the mri related requirements inclusion criteria healthy persons: * age: 20-50 year * no history of low back pain * a score of 0% on the oswestry disability index * willingness to sign the informed consent * met the mri related requirements exclusion criteria: * history of major trauma and/or major orthopedic surgery of the spine, the pelvis or the lower quadrant * one of the following conditions: parkinson, ms, stroke with sequels.... * radicular symptoms * not dutch-speaking * strong opioids * neck pain * ankle problems * smoking

Keywords: low back pain proprioception postural control spine variability mri vibration brain
study of tq-b3139 versus crizotinib in the first line treatment of subjects with anaplastic lymphoma kinase (alk) positive non-small cell lung cancer (nsclc)

Conditions: ALK-positive NSCLC

Summary: to evaluate the efficacy and safety of tq-b3139 versus crizotinib in subjects with alk-positive nsclc that have received one chemotherapy regimen and have not received alk inhibitor.


Eligibility criteria:
inclusion criteria: * 1.18 and 75 years. 2. eastern cooperative oncology group (ecog) performance status score of 0 to 1. 3. life expectancy ≥12 weeks. 4. histologically or cytologically confirmed advanced or metastatic nsclc with alk-positive. 5. has not received alk tyrosine kinase inhibitor (tki). 6. has received one chemotherapy regimen for stage iiib-iv nsclc. 7. at least one measurable lesion. 8. adequate organ system function. 9. understood and signed an informed consent form. exclusion criteria: * 1. has diagnosed and/or treated additional malignancy within 5 years prior to randomization. exceptions include cured cancer carcinoma in situ of the cervix, intramucosal carcinoma of gastrointestinal tract, breast and melanoma skin cancers and superficial bladder tumors. 2. hypersensitivity to tq-b3139 or crizotinib. 3. has received any cancer therapy within 4 weeks or 5 times of t1/2. 4. has received any major surgery within 4 weeks. 5. has received any radiotherapy or minor surgery aimed to cure cancer within 2 weeks. 6. acute toxicity that is ≥ grade 2 caused by previous cancer therapy. 7. has active viral, bacterial and fungal infections within 2 weeks before the first dose. 8. has serious cardiovascular disease within 3 months before the first dose. 9. has currently uncontrollable congestive heart failure. 10. has continuous arrhythmia ≥ grade 2, uncontrollable atrial fibrillation or qtc interval \> 480ms. 11. has interstitial fibrosis or interstitial lung disease ≥ grade 3. 12. brain metastases with symptom. 13. hbsag positive and hbv dna positive (≥uln);hcv antibody and hcv-rna positive (≥uln); hiv positive or ≥hiv uln. 14. has multiple factors affecting oral medication. 15. has received a strong cyp3a inhibitors within 7days before the first dose. 16. has received a strong cyp3a inducers. 17. breastfeeding or pregnant women.; men unwilling to use adequate contraceptive measures during the study. 18. according to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
a contralateral dispensing clinical trial of study test silicone hydrogel lens against enfilcon a silicone hydrogel lens

Conditions: Myopia

Summary: this will be a 1-month dispensing, double-masked, randomized, contralateral study comparing the test lens against the control lens. the assignment of lenses to eyes (i.e. which lens type is to be worn in which eye throughout the study) will be selected according to a randomization table.

both test and control lenses will be used in a daily wear modality for 1 month. it is anticipated that this study will involve the following visits: baseline (screening and dispense visit combined), 2-week visit and 4-week visit.

Eligibility criteria:
inclusion criteria: * is at least 17 years of age and has full legal capacity to volunteer * has read and understood the information consent letter * is willing and able to follow instructions and maintain the appointment schedule * is correctable to a visual acuity of 20/30 or better (in each eye) with their habitual correction or the assigned study lenses * is an adapted soft contact lens wearer (for the purpose of this study: current lens wear at least 3 days per week, 8 hours each day.) exclusion criteria: * is participating in any concurrent clinical or research study * has any known active\* ocular disease and/or infection; * has a systemic condition that in the opinion of the investigator may affect a study outcome variable * is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable\^ * has known sensitivity to the diagnostic pharmaceuticals to be used in the study * is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit). rationale is that systemic changes over time due to pregnancy/lactating may adversely affect contact lens wear e.g. ocular dryness may increase. * is aphakic * has undergone corneal refractive surgery. for the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active. participants will be excluded with significant slit lamp findings (e.g. infiltrates or other slit lamp findings grade 3 or above: corneal edema, tarsal abnormalities, and conjunctival injection) or active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology). \^ for the purposes of this study, participants will be excluded, if currently taking medication, such as oral antihistamines, antihistamine eye drops, oral and ophthalmic beta-adrenergic blockers (e.g. propanolol, timolol), anticholinergics, oral steroids and any prescribed or over-the-counter eye medication, except artificial tears or eye lubricants
comparison of pre- and post-discharge initiation of lcz696 therapy in hfref patients after an acute decompensation event

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: to explore two modalities of treatment initiation (pre-discharge, and post-discharge) with lcz696 in hfref patients following stabilization after an adhf episode.


Eligibility criteria:
inclusion criteria: 1. patients hospitalized due to acute decompensated hf episode (adhf) as primary diagnosis) and consistent signs \& symptoms 2. diagnosis of hf new york heart association class ii-to-iv and reduced ejection fraction: left ventricular ejection fraction ≤ 40% at screening 3. patients did not receive any iv vasodilators (except nitrates), and/or any iv inotropic therapy from the time of presentation for adhf to randomization 4. stabilized (while in the hospital) for at least 24 hours leading to randomization. 5. meeting one of the following criteria: * patients on any dose of acei or arb at screening * acei/arb naïve patients and patients not on acei or arb for at least 4 weeks before screening. exclusion criteria: 1. history of hypersensitivity to the sacubitril, valsartan, or any arbs, nep inhibitors or to any of the lcz696 excipients. 2. symptomatic hypotension and/or a sbp below 110 mm hg or sbp above 180 mm hg prior to randomization 3. end stage renal disease at screening; or estimated gfr below 30 ml/min/1.73 m2 (as measured by mdrd formula at randomization. 4. serum potassium above 5.4 mmol/l at randomization. 5. known history of hereditary or idiopathic angioedema or angioedema related to previous ace inhibitor or arb therapy 6. severe hepatic impairment, biliary cirrhosis and cholestasis

Keywords: acute decompensated heart failure reduced ejection fraction pre-discharge treatment post-discharge treatment angiotensin receptor neprilysine inhibitor hfref
follow up safety study of sch 420814 in subjects with parkinson's disease (p05175)

Conditions: Parkinson Disease; Neurodegenerative Diseases; Central Nervous System Diseases; Movement Disorders; Brain Diseases

Summary: the purpose of this study is to assess the long term safety of sch 420814 (preladenant) in participants with moderate to severe parkinson's disease who are taking an l-dopa/dopa decarboxylase inhibitor and/or dopamine agonist. all participants must have participated in the main study (p04501; nct00406029) entitled "a phase 2, 12 week, double blind, dose finding, placebo controlled study to assess the efficacy and safety of a range of sch 420814 doses in subjects with moderate to severe parkinson's disease experiencing motor fluctuations and dyskinesias."


Eligibility criteria:
inclusion criteria: * participants must have participated in p04501. * participants must be \>=30 years of age, with a diagnosis of moderate to severe idiopathic parkinson's disease. * participants must have been on a regimen of l-dopa and/or a dopamine agonist. exclusion criteria: * participants who discontinued from study p04501 because they experienced a serious adverse event (sae) * participants with any form of drug-induced or atypical parkinsonism, cognitive impairment, or psychosis * participants taking tolcapone * participants who are participating in any other clinical study
oral β-alanine supplementation in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: preliminary evidence suggest that patients with chronic obstructive pulmonary disease (copd) suffer from lower-limb muscle dysfunction. this may, at least in part, be due to a combination of physical inactivity and muscle oxidative stress. pilot data (not published) clearly show that patients with copd have significantly lower carnosine, which is a ph (acidity-basicity level) buffer and antioxidant, levels in the m. vastus lateralis compared to healthy subjects. beta-alanine supplementation has shown to increase muscle carnosine in trained and untrained healthy subjects. this study will assess if muscle carnosine can be augmented by beta-alanine supplementation in 40 copd patients (20 patients receive beta-alanine, 20 patients receive placebo). 10 healthy elderly controls will also be assessed to compare baseline muscle carnosine levels. the aims of this study are to: 1. investigate baseline muscle carnosine levels to confirm the pilot data in a larger sample of patients with copd compared with healthy elderly subjects 2. investigate if beta-alanine supplementation augments muscle carnosine in copd patients and whether it has an influence on exercise capacity, lower-limb muscle function and quality of life 3. to investigate baseline and post supplementation structural and metabolic muscle characteristics and markers of oxidative stress and inflammation in copd patients and it's association with muscle carnosine levels


Eligibility criteria:
inclusion criteria: * copd: diagnosis of moderate to very severe copd according to global initiative for chronic obstructive lung disease (gold) guidelines * healthy controls: forced expiratory volume at one second/forced vital capacity (fev1/fvc) \> 0.7, matched for age and gender exclusion criteria: * the presence of known instable cardiac disease * neurological disease and/or musculoskeletal disease that preclude safe participation in an exercise test * a history of drugs/alcohol abuse * vegetarianism * inability to understand the flemish language. copd-specific exclusion criteria: * copd exacerbation and/or hospitalization in the last 6 weeks * participation in pulmonary rehabilitation in the previous 12 months.
an italian experience on grade 3b follicular lymphoma

Conditions: Grade 3b Follicular Lymphoma

Summary: study purpose is to evaluate baseline clinical data, outcome after front-line rituximab containing chemotherapy and survival in patients with grade 3b follicular lymphoma. also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 world health organization (who) criteria.


Eligibility criteria:
inclusion criteria: * diagnosis of grade 3b follicular lymphoma * age \> 18 years * front-line treatment with rituximab containing chemotherapy * availability of histological sample for central review exclusion criteria: * other lymphoma diagnosis

Keywords: grade 3b follicular lymphoma 2016 who criteria front-line treatment rituximab